Norwegen - Norwegisch - Statens legemiddelverk

orifarm as - flutikasonpropionat - inhalasjonsaerosol, suspensjon - 50 mikrog/ dose

Norwegen - Norwegisch - Statens legemiddelverk

glaxosmithkline as - flutikasonpropionat - inhalasjonsaerosol, suspensjon - 50 mikrog/ dose

Norwegen - Norwegisch - Statens legemiddelverk

glaxosmithkline as - flutikasonpropionat - inhalasjonsaerosol, suspensjon - 125 mikrog/ dose

Norwegen - Norwegisch - Statens legemiddelverk

glaxosmithkline as - flutikasonpropionat - inhalasjonsaerosol, suspensjon - 250 mikrog/ dose

Norwegen - Norwegisch - Statens legemiddelverk

glaxosmithkline as - flutikasonpropionat - inhalasjonspulver, dosedispensert - 50 mikrog/ dose

Norwegen - Norwegisch - Statens legemiddelverk

glaxosmithkline as - flutikasonpropionat - inhalasjonspulver, dosedispensert - 100 mikrog/ dose

Norwegen - Norwegisch - Statens legemiddelverk

glaxosmithkline as - flutikasonpropionat - inhalasjonspulver, dosedispensert - 250 mikrog/ dose

Norwegen - Norwegisch - Statens legemiddelverk

glaxosmithkline as - flutikasonpropionat - inhalasjonspulver, dosedispensert - 500 mikrog/ dose

Norwegen - Norwegisch - Statens legemiddelverk

orifarm as - flutikasonpropionat - inhalasjonsaerosol, suspensjon - 50 mikrog/ dose

Europäische Union - Norwegisch - EMA (European Medicines Agency)

regeneron ireland designated activity company (dac) - cemiplimab - karsinom, squamous cell - antineoplastiske midler - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.